PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed supratentorial anaplastic glioma with a
recurrent cyst requiring aspiration for symptom control Measurable cystic lesion confirmed
by contrast-enhanced CT or MRI At least 3 months since radiotherapy to site of measurable
disease unless unequivocal evidence of tumor progression Neoplastic cell reactivity with
tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a
monoclonal murine antibody

PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50-100%
Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater
than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 1.5 times normal
Alkaline phosphatase less than 1.5 times normal Renal: Creatinine less than 1.2 mg/dL
Other: Negative pregnancy test Effective contraception required of fertile women

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks
since antineoplastic chemotherapy unless unequivocal evidence of tumor progression
Endocrine therapy: Corticosteroids allowed if at lowest possible dose and dose stable for
at least 10 days prior to entry Radiotherapy: See Disease Characteristics Surgery: Not
specified